In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.
In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke
A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde